NEWPORT BEACH, CA. October 6, 2016 – CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, will host a webinar with Sarepta Therapeutics, Inc. (NASDAQ: SRPT) on October 11 at 1 p.m. ET/10 a.m. PT to provide the Duchenne community an overview of Sarepta’s patient support program, SareptAssist.
The webinar will address patient referrals, consideration for starting therapy, case management process and financial assistance programs. The webinar will be presented by Dan Madden, Director of Patient Services, Sarepta Therapeutics, and moderated by Dr. Mike Kelly, CureDuchenne’s Chief Scientific Officer. To learn more, please visit www.SareptAssist.com.
Duchenne muscular dystrophy is a fatal genetic disease that causes muscle degeneration and affects 1 in 3,500 boys. Boys with Duchenne are usually diagnosed by age 5, lose their ability to walk by age 12 and most don’t survive their mid-20s. CureDuchenne provided early funding and support to Sarepta Therapeutics that contributed to the development of eteplirsen.
To register for the webinar on October 11, click here. The call in number is (844) 337-8088 and the conference ID number is 93592813.
CureDuchenne was founded in 2003 with a focus on saving the lives of those with Duchenne muscular dystrophy, a disease that affects more than 300,000 children and young adults worldwide. With support from CureDuchenne, nine research projects have advanced to human clinical trials. CureDuchenne also brings physical therapy and standard of care to local communities around the country through its CureDuchenne Cares program. For more information, please visit CureDuchenne.org and follow us on Facebook, Twitter, Instagram and YouTube.